GlobeNewsWire
26 Sept 2025, 12:30 UTC · 51w ago
Verdict
Headline takes no side. We score INBS +0.30 across three claims — moderately bullish.
+0.30moderately bullish
More positive than 60% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Intelligent Bio Solutions anticipates FDA 510(k) clearance for its drug screening system in the second half of 2026.
More negative than 86% of claims this week
The company must conduct new clinical studies before the end of 2025 to gather additional supporting data following FDA feedback.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 78% of claims this week
The Intelligent Fingerprinting Drug Screening System has been adopted by over 450 accounts across 24 countries.
More positive than 52% of claims this week
Which stocks this story touches
More positive than 60% of ticker scores this week
The company is advancing its FDA submission process and reporting global growth, although the timeline for clearance has been extended to 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
8h ago
−86.6%
Price is moving against the score
$1.71 vs $12.80 close before publication (Sep 25) · not market-adjusted
INBS chart →
